Loading clinical trials...

Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI) | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)

A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)

NCT01650051•Amneal Pharmaceuticals, LLC

View on ClinicalTrials.gov

Summary

The primary objective is to evaluate the safety and efficacy of Phenazopyridine HCl Tablets, USP 200 mg as a short term analgesic treatment of pain upon urination associated with Uncomplicated Urinary Tract Infections (uUTI). The secondary exploratory objective is to evaluate safety and efficacy of Phenazopyridine HCl Tablets, USP 200 mg as a short term analgesic treatment of burning upon urination associated with uUTI.

Detailed Description

Subjects will make separate self-assessments for severity of pain and burning upon urination using the NRS and self-assessments of their discomfort using the GSAS at designated intervals for 24 hours. Subjects will rate the effectiveness of the study medication using the SASMS at a designated interval for 24 hours.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Is willing and able to provide and understand written informed consent for the study.
•Is a female 18 years of age or older.
•Has a clinical diagnosis of uncomplicated urinary tract infection (uUTI).
•Has a reported history indicating a diagnosis of cystitis or urethritis.
•Has a positive urine dipstick test showing the presence of nitrate or leukocyte esterase.
•Has moderate to severe pain (score of 4 to 10 inclusive on the NRS) and burning (score of 4-10, inclusive on the NRS) upon urination.
•Is willing and able to understand and comply with the requirements of the study.
•Each female subject of childbearing potential (excluding women who are surgically sterilized or postmenopausal for at least 2 years) must have a negative urine pregnancy test at Screening and must be willing to use an acceptable form of birth control during the study. For the purpose of this trial, the following are considered acceptable methods of birth control: oral contraceptives, contraceptive patches, contraceptive implant, vaginal contraceptive, double barrier methods (eg, condom and spermicide), contraceptive injection (Depo-provera®), intrauterine device (IUD), hormonal IUD (Mirena®), and abstinence with a documented second acceptable method of birth control should the subject become sexually active.

Exclusion Criteria

•Is pregnant or breastfeeding during the study.
•Has a diagnosis of a urinary tract or kidney disorder that is not a uUTI. Has a diagnosis of pyelonephritis (kidney infections when lower uUTI spreads to the upper tract).
•Has taken an analgesic within 1 day prior to Visit 1.
•Has taken any systemic anti-infectives within 7 days prior to Visit 1.
•Has a history of G-6-PD deficiency or hemolytic anemia.
•Has a known history of anatomical genitourinary (GU) anomalies or GU surgery within 6 months prior to Visit 1.
•Has a chronic infection of the urinary tract requiring an intravenous pyelogram (IVP), ultrasound, or cystoscopy.
•Is unable to comprehend the language of the informed consent and the self-evaluation scales.
•Has serious acute illness (e.g., pneumonia) or an untreated or unstable medical illness that would likely interfere with assessments of uUTI.
•Has received an investigational medication as part of a drug trial within 3 months prior to Visit 1.
+7 more criteria

Locations (1)

Symbio, LLC

Port Jefferson, New York, United States

Key Dates

Start Date

February 1, 2012

Primary Completion Date

February 1, 2013

Completion Date

February 1, 2014

Last Updated

June 26, 2014

Enrollment

424

ACTUAL participants

Conditions

Uncomplicated Urinary Tract Infections

Interventions

Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg

DRUG

Phenazopyridine Hydrochloride Tables, USP 200 mg

DRUG

Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women

NCT03354598

Uncomplicated Urinary Tract Infections

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 26, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions